Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Italian regions testing for signs of coronavirus immunity

Published 04/06/2020, 12:43 PM
Updated 04/06/2020, 01:18 PM
© Reuters. The outbreak of the coronavirus disease (COVID-19) in Milan

By Riccardo Bastaniello

PADUA, Italy (Reuters) - Authorities in northern Italy have begun testing health workers for antibodies that may help identify individuals with immunity to the coronavirus as they look for ways to ease the lockdown imposed a month ago to contain the epidemic.

On Monday, the northeastern region of Veneto, which saw one of Italy's earliest outbreaks of the disease in February, started blood tests on health workers, following neighbouring Emilia Romagna, which began testing last week.

"I can announce that the blood tests on health workers have begun," said regional governor Luca Zaia.

Following an initial phase of testing on 2,000-3,000 health workers, tests are to be extended to staff and residents in nursing homes and workers in contact with the public.

Zaia said the aim would ultimately be to allow authorities to issue "licences" for individuals with proven immunity to the virus to return to work.

The tests come as the number of deaths and infections has flattened out and the government has begun considering the so-called phase 2 stage of the crisis, when businesses and industry closed during the lockdown can start to reopen.

The total number of confirmed cases increased by just 3,599 on Monday to 132,547, the lowest daily rise since March 17, while the number of deaths rose 636 to 16,523 - just under a quarter of all the fatalities registered so far in the world.

With Italy's fragile economy facing the most serious collapse since World War Two, authorities are desperate to restart production while avoiding a second wave of infections that could reignite the epidemic.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

But in the absence of a cure or vaccine, the response has been hampered by the many unknown aspects of the virus and uncertainty over whether immunity can be developed against it.

The tests, which look for antibodies produced by the immune system in response to the illness, are simpler than the swab tests on mucus used to find the virus itself, but there is some doubt about whether they can yield reliable results.

"Some say they will work, others say they won't," Zaia told a daily briefing. "It all has to be proven but that's how vaccines are made as well."

The blood tests, which produce results much more quickly than swab testing, aim to identify two types of antibodies - one which shows contact with the virus and a second which would indicate whether the body has developed a defence against it.

"We've begin verifying whether these tests are effective and whether they concord with molecular analysis," said Andrea Crisanti, a professor of virology at the University of Padua, which is carrying out the testing with the University of Verona.

"I think that within two weeks or a month we will have enough data to be able to have a certain level of confidence," he told Reuters.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.